Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBOLD: ATA188 in Progressive Multiple Sclerosis
NCT03283826Phase 2Terminated
- Sponsor
- Atara Biotherapeutics
- Start
- Oct 2017
- Primary completion
- Nov 2023
- Modality
- Native Immune Cells
- Countries
- 3
01
Overview
A Phase 2 trial of ATA188 in primary progressive multiple sclerosis (PPMS), secondary-progressive multiple sclerosis (SPMS), sponsored by Atara Biotherapeutics. Started Oct 2017; status: terminated.
02
Drugs
ATA188
03
Conditions
primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT03283826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283826.